1. Introduction {#sec1-molecules-24-00640}
===============

The success of nuclear medicine (NM) has been intimately linked to the availability of new radionuclides (RNs) and the discovery of new radiopharmaceuticals. The field of radiopharmaceuticals is constantly evolving thanks to the great contributions of specialists coming from different disciplines such as physics, inorganic and organic chemistry, radiochemistry, biochemistry, pharmacology, nuclear medicine, and so on. In particular, the research and applications of radiometals for nuclear therapy have experienced a great increase thanks to the development of radionuclide and radiopharmaceutical production technologies, the availability of innovative synthetic strategies, and tools useful for preclinical studies.

The employment of therapeutic radiometals is regulated by their physical characteristics, such as half-life, radiation emission energy and type (β-, γ, auger, α), availability, and chemical ability to coordinate with ligands. In recent years there has been intense research in the field of production and application of conventional therapeutic radionuclides (such as ^131^I, ^90^Y, ^177^Lu, ^188^Re, ^186^Re, ^153^Sm, ^169^Er, ^89^Sr, etc.) ([Table 1](#molecules-24-00640-t001){ref-type="table"}) compared with emergent therapeutic radionuclides (such as ^67^Cu, ^47^Sc, ^223^Ra, ^166^Ho, ^161^Tb, ^149^Tb, ^212^Pb, ^212^Bi, ^225^Ac, ^213^Bi, ^211^At, etc.) ([Table 2](#molecules-24-00640-t002){ref-type="table"}) \[[@B1-molecules-24-00640],[@B2-molecules-24-00640],[@B3-molecules-24-00640],[@B4-molecules-24-00640],[@B5-molecules-24-00640],[@B6-molecules-24-00640],[@B7-molecules-24-00640],[@B8-molecules-24-00640],[@B9-molecules-24-00640],[@B10-molecules-24-00640],[@B11-molecules-24-00640],[@B12-molecules-24-00640],[@B13-molecules-24-00640],[@B14-molecules-24-00640],[@B15-molecules-24-00640],[@B16-molecules-24-00640],[@B17-molecules-24-00640],[@B18-molecules-24-00640],[@B19-molecules-24-00640],[@B20-molecules-24-00640],[@B21-molecules-24-00640],[@B22-molecules-24-00640],[@B23-molecules-24-00640],[@B24-molecules-24-00640],[@B25-molecules-24-00640],[@B26-molecules-24-00640],[@B27-molecules-24-00640],[@B28-molecules-24-00640]\]. The great effort that researchers have put in this particular therapeutic field of nuclear medicine is comparable with the research that has been carried out in the last 10 years on Tc-99m alternative production methods \[[@B29-molecules-24-00640],[@B30-molecules-24-00640]\].

New treatment strategies such as the theranostic personalized approach have given a great impulse to the research in this particular field of therapeutic medicine. This approach is based on the association of β^−^ and γ-radiation, which is advantageous in monitoring radiopharmaceutical distribution and therapeutic effects with scintigraphy methods \[[@B27-molecules-24-00640]\]. There are different suitable combinations of molecular targeting vectors and radionuclides for theranostics use. The first is multiple-element theranostics radiopharmaceuticals (different elements showing similar chemical properties---but with different physical emission properties---that are used with the same bioactive molecule, e.g., ^188^Re with ^99m^Tc, ^68^Ga with ^177^Lu or ^90^Y), where one is used for therapeutic tumor treatment and the other is used for diagnosis and response monitoring. Even better is single-element theranostics radiopharmaceuticals, where a bioactive molecule is targeted by different isotopes of the same element with complementary diagnostic and therapeutic properties (e.g., ^43,44^Sc and ^47^Sc) ([Table 3](#molecules-24-00640-t003){ref-type="table"}), or with a single radioisotope of a single element with both diagnostic and therapeutic emissions (e.g., ^64^Cu suitable for positron emission tomography, PET, imaging and therapy) ([Table 4](#molecules-24-00640-t004){ref-type="table"}).

The present study has the aim of specifically analyzing the research output on therapeutic radiometals from 2008 (January) to 2018 (October). In this period, authors have quantitatively first, and qualitatively after, analyzed and interpretated this scientific trend. Two databases were taken into consderation: Web of Science (WoS) and Scopus. WoS has been for a long time the only available resource for large-scale bibliometric data, and still today remains the only choice for the scientific impact evaluation of publications before the mid-1990s. The system core, slowly but constantly expanding, is confined in the WoS Core Collection, which indexes over 12,000 journals, 150,000 conference proceedings, and 60,000 monographs, with another 75,000 already pre-announced. WoS selects and discards sources within certain stringent qualitative and quantitative criteria, guided (and justified) by bibliometric rules. Qualitative parameters, besides the obvious peer review requirement, include publication punctuality, English language (at least for titles, abstract, and keywords sections), author and editorial board cosmopolitanism, and editorial content innovation and adequacy, which are ascertained on the basis of a bibliometric mapping of the existing periodic literature.

Quantitative parameters, on the other hand, include impact factor, total number of citations, self-citation percentage, and authors' citation score (H index).

Overall, the application of these criteria for the WoS selection confirms its elective affinities with the European and North American periodic literature written in English in the natural and biomedical sciences field.

Despite being a newer database, Scopus (from Elsevier) boasts an impressive coverage: over 20,000 peer reviewed journals, 400 trade publications, 370 book series, and 6 milion conference papers coming from proceedings and journals. Moreover, thanks to its integration with the Scirus search engine, millions of scientific patents and web pages are also retrievable from the Scopus database. Sources are selected based on qualitative and quantitative criteria similar to those used by WoS, but with greater weight on qualitative over quantitative parameters independent of the IF value. The selection is not an exclusive affair of Elsevier's editorial staff, but avails itself of the advice of an independent Content Selection and Advisory Board (CSAB) made up of scientists and librarians from various geographical and disciplinary backgrounds. On the geographical-linguistic level, Scopus is more ecomenical than WoS. More than half of its content comes from areas other than North America. The European presence is especially massive, and over 20% of sources in languages other than English. From the disciplinary point of view, over 70% of the literature collected comes from the physical and biomedical sciences field \[[@B32-molecules-24-00640]\].

Academic journals have published a large number of papers in the therapeutic NM research field in the last 10 years. Despite this, a literature analysis has never been made before to address the research interest and potential of therapeutic radionuclides \[[@B33-molecules-24-00640]\]. For this reason the present study aims to specifically analyze the research output regarding therapeutic radiometals from within the past decade, with intent to quantify and identify the global trend of scientific literature and emphasize the interdisciplinary nature of this research field.

2. Results and Discussion {#sec2-molecules-24-00640}
=========================

2.1. The Worldwide Output {#sec2dot1-molecules-24-00640}
-------------------------

An analysis of global trends was conduced by comparing the data collected by consulting both Scopus and Web of Science (WOS) databases on 16 October 2018 from 3 to 6pm.

In [Table 5](#molecules-24-00640-t005){ref-type="table"}a,b, the total data extracted from both databases are listed. The data represent the total number of articles, articles in press, reviews, notes, and short surveys (generally called "papers" for the sake of simplicity) for each radionuclide over the decade. Finally, the radionuclides are divided in two categories: conventional (CRNs) and emergent (ERNs) radionuclides.

A comparison of the total number of papers extrapolated by Scopus vs. WoS (CRNs: 10339 vs. 8435, ERNs: 2378 vs. 1870, respectively) determined the Scopus database as the better source of data for use in the following numeric analysis of literature. This discrepacy can be explained by the less restrictive selection criteria used by Scopus, which favors qualitative over quantitative parameters without restrictions on the journal IF. The database choice is therefore justified, considering the lack of scientific production extrapolated for some radionuclides in particular, including ^149^Tb, ^211^At, and ^186^Er.

2.2. Annual Trend Evaluation {#sec2dot2-molecules-24-00640}
----------------------------

A first analysis of Scopus-collected data of the past 10 years ([Figure 1](#molecules-24-00640-f001){ref-type="fig"}) indicates a consistent annual production of scientific publications discussing conventional therapeutic radionuclides. Since 2012, however, a significant increase of publications concerning emergent radionuclides is noticeable. In order to identify which radionuclides have particularly drawn the scientific community's attention, [Table 6](#molecules-24-00640-t006){ref-type="table"} and [Table 7](#molecules-24-00640-t007){ref-type="table"} explicit the annual number of scientific production per radionuclide. [Table 6](#molecules-24-00640-t006){ref-type="table"} summarizes the data for conventional radionuclides, and from the data a scientific production stability can be gauged, in particular for Sm-153, Sr-89, and Y-90, with a significative difference in the absolute values for single radionuclides. As regards I-131, there is a significant decline in the number of publications since 2015. This is due to a few different factors: (1) the "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer", published by the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, which has scaled down the use of thyroid ablative treatment; (2) the important prognostic value of PET with ^18^F-FDG, which has limited the use of treatments in patients refractory to iodine; (3) the availability of alternative treatments with biological drugs; and ultimately, (4) the greater interest of researchers towards more innovative therapies. A slight decline characterizes the scientific output related to renium isotopes, which is reasonably matched by the number of Lu-177 publications slowly but constantly growing since 2012 ([Figure 2](#molecules-24-00640-f002){ref-type="fig"}). On the other hand, [Table 7](#molecules-24-00640-t007){ref-type="table"} represents the publication distribution for each emergent radionuclide per year. Unsurprisingly, scientific production on Ra-223 substantially rose in the second half of the decade ([Figure 3](#molecules-24-00640-f003){ref-type="fig"}), certainly a result of the marketing authorization of Xofigo (Ra-223 dichloride radiopharmaceutical by Bayer AG) issued by the European Medicines Agency in 2013 \[[@B34-molecules-24-00640]\]. Similarly, in the past two years, scientific literature on Ac-225 has also started experiencing a rise, probably thanks to the increased availability and improved radiochemistry of alpha particle-emitting nuclides for targeted therapy.

2.3. Interdisciplinary Nature of Research {#sec2dot3-molecules-24-00640}
-----------------------------------------

In order to bring out the multidisciplinary nature of the research in this field, a comparative analysis of the bibliometric data categorized in terms of Journal Subject Areas (JSA) was performed. JSA have been grouped into three large macro-areas (physics, chemistry and biology, and pharmacology and medicine) and divided into each radionuclide. From the analysis of the data relating to conventional radionuclides ([Figure 4](#molecules-24-00640-f004){ref-type="fig"}) that have been widely studied and employed in the last decade, it is clear that researchers who deal with preclinical and clinical application are very (and almost comparably) active. On the other hand, literature regarding the production of conventional radionuclides under the macro-area of physics is poor. Moreover, an in-depth analysis of the publications under this last macro-area indicates that the majority of the publications concern dosimetry studies.

On the contrary, the data relating to emergent radionuclides ([Figure 5](#molecules-24-00640-f005){ref-type="fig"}) display a significant contribution from areas related to physics, in particular in the case of Cu-67, for which almost 50% of the publications belong to journals of physics, 38% consist of preclinical studies, and only 13% come from studies related to human application. Sc-47 (37% of the 65 publications), and Sn-117m (55% of the 315 publications) are also notable. Regarding Ac-225 and Bi-213, most of the work in the last 10 years has been done on preclinical (Ac-225 = 53% of the 231 publications, Bi-213 = 51% of the 252 publications, At-211 = 54% of the 75 publications) and clinical (Ac-225 = 34% of the 231 publications, Bi-213 = 43% of the 252 publications) studies. Regarding the pair Pb-212 and Bi-212, the majority of the works belongs to the preclinical field (57% of the 14 publications). Finally, and not surprisingly, Ra-223 was dominant in clinical studies, with 60% of works belonging to the medical area.

2.4. Country Research Distribution {#sec2dot4-molecules-24-00640}
----------------------------------

For each publication, authors' country of origin was extrapolated and elaborated on to map the global research interest and involvement of human and financial resources. From a preliminary assessment classified by the type of radionuclide, 98 countries study conventional radionuclides while only 85 study emergent radionuclides. Out of a total 98 countries, it turns out that five Asian countries, two countries on the American continents, and six European countries are involved only in research on conventional radionuclides.

In [Figure 6](#molecules-24-00640-f006){ref-type="fig"}, the percentage of publications per continent when compared to the total number of publications produced in the past 10 years is reported for both conventional and emergent radionuclides. This analysis reveals that European researchers are authors or co-authors of almost half of the publications on both conventional and emergent radionuclides. Papers collected without reference to a country were place in the "undefined" category.

From the list of countries involved in this research field it was also possible to draw up the top 20 countries with the most active researchers ([Figure 7](#molecules-24-00640-f007){ref-type="fig"} and [Figure 8](#molecules-24-00640-f008){ref-type="fig"}).

At first it is evident that, even if they are in a different order, the countries of the two top 20s are the same. Deepening the analysis however, we notice that USA and Germany rank high in both top 20s, while China slides down from the third position in the conventional radionuclides top 20 to the fifth position regarding emerging radionuclides, thus highlighting a lower investment in human and financial resources. This is similar to Italy, which slides down from fourth to sixth position. On the contrary, the United Kingdom and France both gain two positions from the conventional to emergent radionuclide top 20.

The percentage of publications, expressed for each conventional and emergent radionuclide, has been calculated for all 98 and 85 countries respectively. However, we in [Table 8](#molecules-24-00640-t008){ref-type="table"} and [Table 9](#molecules-24-00640-t009){ref-type="table"} the results just for the top-20 countries of the two categories.

In [Table 8](#molecules-24-00640-t008){ref-type="table"} and [Table 9](#molecules-24-00640-t009){ref-type="table"}, however, we show the results only of the the top-20 countries of the two categories.

All countries, at varying rates, studied almost all radionuclides except for Erbium-186. Out of this list we must report Taiwan (rank = 23) that produced 7.24% of the publications on Re-188, giving it fourth place. Similarly, the Czech Republic (rank = 25) tied with USA and Italy by producing 6.52% of the publications on Er-186.

Out of this list we must report the Czech Republic (rank = 21), which produced 6.02% of the publications on Sc-47, thus gaining the third place tied with Japan. Similarly, Hungary (rank = 26) tied the Russian Federation by producing 11.54% of the publications on Tb-161.

Denmark (rank = 24) produced 10.91% of the publications on At-111, placing it third.

Analyzing the total amount of affiliations and papers for each category of radionuclide (CRN or ERN) reported in [Table 10](#molecules-24-00640-t010){ref-type="table"}, it can be deduced that the larger the number of affiliations when compared to the number of publications (12820 over 10339 for CRNs and 3372 over 2378 for ERNs), the higher the grade of cooperation between that countries in this scientific sector.

3. Materials and Methods {#sec3-molecules-24-00640}
========================

3.1. The Worldwide Output {#sec3dot1-molecules-24-00640}
-------------------------

With the aim to quantify and identify a global trend of scientific literature from the past decade in regards to the interdisciplinary nature of research on therapeutic radionuclides, bibliometric data (number of papers, year of publication, authors' country of origin) was collected by consulting Scopus (<https://www.scopus.com>) and Web of Science (WOS) (<http://apps.webofknowledge.com>) databases on 16 October 2018 from 3 to 6 pm.

The selection criteria used to refine data collection concerned the following: (1) the search combination terms placed the OR boolean operator among different nomenclature of radionuclides (e.g., ^67^Cu, Cu-67, Copper-67); (2) the search terms were limited to article title, abstract, and keywords; (3) output from the search were further selected by limiting the type of publication via followig filters: article, article in press, note, short survey, review, and letter. Congress abstracts were excluded due to the less-strict peer review selection to which they are subjected.

The final refined data, reported in [Table 5](#molecules-24-00640-t005){ref-type="table"}a,b, was finally divided into two classes of radionuclides: coventional (^131^I, ^90^Y, ^177^Lu, ^188^Re, ^186^Re, ^153^Sm, ^89^Sr, ^186^Er) and emergent (^67^Cu, ^47^Sc, ^223^Ra, ^166^Ho, ^161^Tb, ^149^Tb, ^212^Pb/^212^Bi, ^225^Ac, ^213^Bi, ^211^At, ^117m^Sn).

Scopus was selected as the database of reference for all subsequent analysis, and the list of publications by radionuclide was exported as file.csv (through the function "export refine"). The file was converted to an xls spreadsheet and elaborated upon with Microsoft Office Excel.

3.2. Annual Analysis of Scopus Data Collected {#sec3dot2-molecules-24-00640}
---------------------------------------------

The data in the xls sheet was divided by year of publication and the ∑ (sum) function was applied to calculate the total number of publications per radionuclide per year, as reported in [Table 6](#molecules-24-00640-t006){ref-type="table"} and [Table 7](#molecules-24-00640-t007){ref-type="table"} and [Figure 1](#molecules-24-00640-f001){ref-type="fig"}, [Figure 2](#molecules-24-00640-f002){ref-type="fig"} and [Figure 3](#molecules-24-00640-f003){ref-type="fig"}.

3.3. Multidisciplinary Nature of Research {#sec3dot3-molecules-24-00640}
-----------------------------------------

In order to highlight the highly multidisciplinary nature of the research of this particular scientific sector and to quantify the contribution to its development given by researchers belonging to various disciplines, the main Journal Subject Area (JSA) was identified for each work. Subsequently, the JSAs were grouped into three large macro-areas, as described in [Table 11](#molecules-24-00640-t011){ref-type="table"}.

For each category of radionuclides (conventional in [Figure 4](#molecules-24-00640-f004){ref-type="fig"} and emergent in [Figure 5](#molecules-24-00640-f005){ref-type="fig"}), the percentage of publications belonging to a specific macro-area for each radionuclide was reported.

3.4. Countries Research Distribution {#sec3dot4-molecules-24-00640}
------------------------------------

For each publication, authors' country of origin was extrapolated and elaborated upon to map the global research interest and involvement of human and financial resources (each country was counted only once per publication if several authors belonged to the same country independently from the institution). The sum of the contribution percentages from each country on conventional and emergent radionuclides was divided into continents and reported in [Figure 6](#molecules-24-00640-f006){ref-type="fig"}. The top 20 countries that most contributed to research on conventional and emergent radionuclides are reported in [Figure 7](#molecules-24-00640-f007){ref-type="fig"} and [Figure 8](#molecules-24-00640-f008){ref-type="fig"}. [Table 8](#molecules-24-00640-t008){ref-type="table"} and [Table 9](#molecules-24-00640-t009){ref-type="table"}, on the other hand, analyze the specific contribution percentage of each country per individual radionuclide.

4. Conclusions {#sec4-molecules-24-00640}
==============

A total of 12,717 publications were analyzed, with 81.3% of the publications discussing conventional RNs while 18.7% discussed emergent RNs. The most investigated therapeutic RNs were I-131, Y-90, Lu-177 among conventional, while Ra-223, followed by Sn-117m, Bi-213, and Ac-225, were favored among emergent RNs. From the analysis the multidisciplinary contributions to this field are evident, but in particular, as expected, most publications came from preclinical and clinical fields in the case of conventional RN, while for the emergent RNs the contribution was weighted towards physics, engineering, and materials science fields. From the geographical point of view, we can see how almost half of the total works were published by Europeans both in regards to conventional and emergent RNs. It is also evident that the high collaboration level between countries was characteristically in line with the multidisciplinary character of this medical sectors. Moreover, we extrapolated a ranking of the top 20 countries for each category. In the top three for conventional RNs were USA, Germany, and China, while for emergent RNs it was USA, Germany, and the United Kingdom.

From this analysis it can be seen that the success of NM has been intimately linked to the availability of new RNs, and that the radiopharmaceuticals field is constantly evolving thanks to the contribution of specialists coming from different disciplines and the collaboration between countries. In recent years, due to the growing interest on new treatment strategies such as the theranostics personalized approach, the research has been centered on the production and application of emergent theranostic radionuclides, such as Cu-67, Sc-47. Alpha emitters, in particular Ra-223 and Ac-225, are also gaining attention, in particular in USA and Germany, and among conventional radionuclides, research on Lu-177 is constantly growing.
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molecules-24-00640-t001_Table 1

###### 

Relevant physical characteristics of principal conventional therapeutic radionuclides \[[@B17-molecules-24-00640],[@B18-molecules-24-00640],[@B19-molecules-24-00640]\].

  Radionuclide   Half-Life   E Max β^−^ (keV)   Production Method
  -------------- ----------- ------------------ -------------------------------
  ^89^Sr         50.5 d      1496               ^88^Sr(n,γ)^89^Sr
                                                ^89^Y(n,p)^89^Sr
  ^90^Y          64.1 h      2280.1             ^89^Y(n,γ)^90^Y
                                                ^90^Sr/^90^Y gen.
  ^117m^Sn       13.6 d      130                ^116^Sn(n,γ)^117m^Sn
                             150                ^117^Sn(n,n',γ)^17m^Sn
                                                ^116^Cd(α,3n)^117m^Sn
  ^131^I         8.02 d      606                ^130^Te(n,γ)^131m,g^Te➔^131^I
  ^153^Sm        46.5 h      808.2              ^152^Sm(n,γ)^153^Sm
  ^169^Er        9.40 d      350                ^165^Ho(p,n)^165^Er
  ^177^Lu        6.73 d      497.8              ^176^Yb(n, γ,β^−^)^177^Lu
                                                ^176^Lu(n,γ)^177^Lu
  ^186^Re        3.72 d      1069.5             ^185^Re(n,γ)^186^Re
                                                ^186^W(p,n) ^186^Re
  ^188^Re        17.0 h      2120.4             ^188^W/^188^Re gen.

molecules-24-00640-t002_Table 2

###### 

Relevant physical characteristics of principal emergent therapeutic radionuclides \[[@B8-molecules-24-00640]\].

  ----------------------------------------------------------------------------------------------------------
  Radionuclide        Half-Life            Energy (keV)                     Production Methods
  ------------------- -------------------- -------------------------------- --------------------------------
  ^67^Cu              2.58 d               E~β~^−^~mean~ = 141\             ^68^Zn(p,2p)^67^Cu\
                                           E~γ~ = 91; 93; 185               ^68^Zn(γ,p)^67^Cu\
                                                                            ^70^Zn(p,α)^67^Cu\
                                                                            ^70^Zn(d,αn)^67^Cu

  ^47^Sc              3.35 d               E~β~^−^~mean~ = 162\             ^47^Ti(n,p)^47^Sc\
                                           E~γ~ = 159                       ^46^Ca(n,γ)^47^Ca → ^47^Sc\
                                                                            ^48^Ca(γ,n)^47^Ca → ^47^Sc

  ^166^Ho             26.82 h              E~β~^−^~mean~ = 665\             ^165^Ho(n,γ)^166^Ho\
                                           E~γ~ = 81                        ^164^Dy(2n,γ)^166^Dy → ^166^Ho

  ^161^Tb             6.89 d               E~β~^−^~mean~ = 154\             ^160^Gd(n,γ)^161^Gd → ^161^Tb
                                           E~γ~ =49; 75                     

  ^212^Pb (^212^Bi)   10.64 h (60.6 min)   E~β~^−^~mean~ = 100\             ^224^Ra/^212^Pb generator
                                           E~γ~ = 238; 300\                 
                                           (E~α~ = 6050; 6089)              

  ^225^Ac             10.0 d               E~α~ = From 5637 to 5830\        ^232^Th(p,2p6n)^225^Ac\
                                           E~γ~ =99.8                       ^226^Ra(p,2n)^225^Ac\
                                                                            ^226^Ra(γ,n)^225^Ra → ^225^Ac

  ^213^Bi             45.6 min             E~α~ = 5558; 5875\               ^225^Ac/^213^Bi generator
                                           E~γ~ = 324                       

  ^223^Ra             11.4d                E~α~ = From 5433 to 5871\        ^227^Ac/^227^Th/^223^Ra gen.
                                           E~γ~ = 144; 154; 269; 324; 338   
  ----------------------------------------------------------------------------------------------------------

molecules-24-00640-t003_Table 3

###### 

Theranostic radioisotopes pair \[[@B31-molecules-24-00640]\].

  Imaging/Therapeutic Pair   T~1/2~            Mode of Decay
  -------------------------- ----------------- -------------------------
  Sc-44/Sc-47                3.9 h / 3.35 d    β^+^; EC; γ/β^−^; γ
  Cu-64/Cu-67                12.7 h / 2.58 d   EC; β^−^; β^+^/β^−^; γ
  Sr-83/Sr-89                32.4 h / 50.5 d   EC; β^+^; γ/β^−^
  Ga-68/Ga-67                68 min / 3.26 d   β^+^/Aug; EC
  Y-86/Y-90                  14.7 h / 2.7 d    EC; β^+^; γ/β^−^
  I-124/I-131                4.2 d / 8.0 d     EC; β^+^; γ/β^−^; γ
  Tb-152/Tb-161              17.5 h / 6.9 d    EC; β^+^; γ/β^−^; γ
  Tb-152/Tb-149              17.5 h / 4.1 h    EC; β^+^; γ/EC; α; β^+^

β^+^ = positrons; β^−^ = beta electrons; C.E. = conversion electrons; Aug. = Auger electrons.

molecules-24-00640-t004_Table 4

###### 

Theranostic radionuclides \[[@B19-molecules-24-00640]\].

  Radionuclide   T~1/2~ (days)   Principal E~γ~ for Imaging, keV (%)   Therapeutic Particle(s)
  -------------- --------------- ------------------------------------- --------------------------------------------
  Sc-47          3.35            159 (68)                              β^−^
  Cu-67          2.58            186 (40)                              β^−^
  Ga-67          3.26            93, 184, 296, (40, 24, 22)            Aug., C.E.
  In-111         2.8             171, 245, (91, 94)                    Aug., C.E.
  Sn-117m        14              159 (86)                              C.E.
  I-123          13.3 h          159 (83)                              Aug., C.E.
  I-131          8               365 (82)                              β^−^
  Sm-153         1.94            103 (30)                              β^−^
  At-211         7.2 h           79 (21)                               α
  Bi-213         46 min          441 (926)                             β^−^; α (from TI-209 → Bi-213 decay chain)

β^−^ = beta electrons; C.E.= conversion electrons; α = alpha particles; Aug. = Auger electrons.

molecules-24-00640-t005_Table 5

###### 

Radionuclide data representing the number of papers extrapolated from the Scopus and Web of Science (WoS) databases published for each radionuclide over the last 10 years (2008--2018). (**a**) Conventional (CRN) vs. (**b**) emergent (ERN).

  a         b                                       
  --------- ------- ------ ----------------- ------ ------
  ^131^I    4458    3764   ^67^Cu            102    119
  ^90^Y     1944    2305   ^47^Sc            65     63
  ^177^Lu   1789    1192   ^223^Ra           1115   642
  ^188^Re   596     411    ^166^Ho           160    137
  ^186^Re   362     181    ^161^Tb           28     181
  ^153^Sm   626     313    ^149^Tb           21     10
  ^89^Sr    528     255    ^212^Pb/^212^Bi   14     41
  ^186^Er   36      14     ^225^Ac           231    145
  Total     10339   8435   ^213^Bi           252    141
                           ^211^At           75     12
                           ^117m^Sn          315    537
                           Total             2378   1870

molecules-24-00640-t006_Table 6

###### 

Annual publications discussing CRNs (2008--2018).

  Topic     2008   2009   2010   2011   2012   2013   2014   2015   2016   2017   2018   TOT
  --------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ -------
  ^131^I    491    429    445    448    475    466    399    404    330    342    229    4458
  ^90^Y     161    163    155    197    194    168    208    197    193    179    129    1944
  ^177^Lu   97     95     89     135    167    144    157    188    244    263    210    1789
  ^188^Re   94     75     58     61     54     53     50     42     46     40     23     596
  ^186^Re   50     40     42     36     44     43     18     23     25     29     12     362
  ^153^Sm   60     70     54     66     69     78     55     63     48     37     26     626
  ^89^Sr    47     54     47     43     77     71     42     41     38     47     21     528
  ^186^Er   5      6      1      6      4      2      6      2      1      0      3      36
  Total     1005   932    891    992    1084   1025   935    960    925    937    953    10339
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###### 

Annual publications discussing ERNs (2008--2018).

  Topic             2008   2009   2010   2011   2012   2013   2014   2015   2016   2017   2018   TOT
  ----------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  ^67^Cu            10     11     7      8      12     5      13     12     6      11     7      102
  ^47^Sc            3      5      3      8      8      5      4      9      6      12     2      65
  ^223^Ra           27     9      22     3      108    142    159    164    152    165    134    1115
  ^166^Ho           15     16     12     16     15     21     13     18     13     8      13     160
  ^161^Tb           0      0      0      1      1      5      6      5      6      2      2      28
  ^149^Tb           1      0      0      5      1      1      4      1      3      3      2      21
  ^212^Pb/^212^Bi   1      0      0      0      4      1      3      0      1      3      1      14
  ^225^Ac           12     9      11     19     23     17     26     18     20     38     38     231
  ^213^Bi           28     22     16     27     22     30     25     21     15     26     20     252
  ^211^At           9      5      3      10     6      8      5      11     3      8      7      75
  ^117m^Sn          28     16     29     26     30     30     43     28     38     25     22     315
  Total             134    93     103    153    230    265    301    287    263    301    248    2378
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###### 

Analysis of the popularity of different conventional radionuclides by the top 20 countries with the highest number of relevant publications (2008--2018). Highlighted in grey are the two highest percentages for each conventional radionuclide.

  Rank   Country          CRN (Contribution % per country)                                                   
  ------ ---------------- ---------------------------------- ------- ------- ------- ------- ------- ------- -------
  1      USA              22.21                              24.72   17.99   18.25   15.66   14.68   21.73   6.52
  2      Germany          5.88                               9.86    14.63   9.05    9.39    5.73    5.73    23.91
  3      China            10.22                              3.85    1.79    11.70   2.92    3.67    4.99    0.00
  4      Italy            5.01                               7.65    7.51    5.15    6.52    6.46    4.11    6.52
  5      United Kingdom   3.83                               3.85    3.93    3.06    5.64    5.14    8.08    2.17
  6      France           4.18                               4.13    3.54    4.18    4.35    4.41    3.08    4.35
  7      Nederland        2.91                               3.61    7.34    2.79    5.22    2.64    2.50    4.35
  8      Japan            5.47                               2.04    0.79    1.11    3.13    1.76    8.32    0.00
  9      India            2.87                               2.52    0.00    5.29    2.71    4.55    4.85    17.39
  10     Switzerland      1.40                               2.88    4.41    1.81    2.09    1.91    1.32    0.00
  11     Canada           1.81                               1.76    3.28    2.65    1.67    2.50    3.08    0.00
  12     Australia        1.47                               2.68    3.32    1.25    2.71    1.76    1.17    0.00
  13     Turkey           2.74                               1.92    1.22    0.84    2.92    1.32    1.17    2.17
  14     South Korea      3.02                               1.40    1.31    2.92    0.84    0.44    0.44    0.00
  15     Iran             1.51                               1.32    2.31    2.51    2.30    7.49    1.32    0.00
  16     Spain            1.86                               2.80    1.00    0.00    4.38    1.91    2.06    4.35
  17     Poland           1.86                               2.36    1.83    1.67    1.46    2.06    0.73    2.17
  18     Sweden           1.05                               1.52    4.93    0.97    1.46    0.59    1.17    2.17
  19     Belgium          1.46                               2.12    1.62    1.67    2.30    1.47    1.47    2.17
  20     Brazil           1.58                               1.28    1.22    0.70    0.63    3.67    0.15    0.00
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###### 

Analysis of the popularity of different emergent radionuclides by the top 20 countries with the highest number of relevant publications (2008--2018). Highlighted in grey are the two highest percentages for each emergent radionuclide.

  Rank   Country              ERN (Contribution % per Country)                                                                           
  ------ -------------------- ---------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  1      USA                  13.48                              13.25   28.73   20.73   3,85    19.35   21.05   35.94   31.97   30      13.99
  2      Germany              9.22                               4.82    8.09    1.22    3.85    9.68    5.26    17.19   22.40   5.45    3.96
  3      United Kingdom       1.42                               2.41    8.57    3.05    3.85    3.23    10.53   2.81    2.19    3.64    1.86
  4      France               6.38                               16.87   4.71    4.88    17.31   9.68    10.53   3.44    5.74    7.27    3.03
  5      China                4.26                               1.20    1.63    1.83    0.00    0.00    5.26    1.88    1.37    3.64    18.65
  6      Italy                2.84                               1.20    4.71    2.44    0.00    0.00    0.00    2.19    1.37    0.91    2.56
  7      Japan                8.51                               6.02    2.05    0.00    1.92    3,23    0.00    1.56    1.09    5.45    7.93
  8      Sweden               1.42                               1.20    2.35    1.83    5.77    3.23    5.26    1.88    3.83    21.82   0.93
  9      Spain                0.71                               0.00    4.59    0.61    0.00    0.00    5.26    0.94    0.55    0.00    1.63
  10     Netherland           1.42                               0.00    1.87    18.90   0.00    0.00    0.00    2.50    3.01    0.00    1.63
  11     Australia            2.13                               0.00    2.41    1.22    0.00    3.23    0.00    4.38    6.56    0.00    0.47
  12     Canada               2.13                               2.41    2.96    0.61    0.00    0.00    0.00    3.75    0.82    2.73    2.80
  13     Switzerland          3.55                               4.82    2.60    1.83    17.31   16.13   5.26    0.94    1.91    0.00    0.93
  14     Russian Federation   5.67                               2.41    1.27    2.44    11.54   9.68    0.00    4.69    2.19    0.91    1.63
  15     India                1.42                               3.61    0.84    5.49    1.92    6.45    5.26    1.25    1.64    0.00    5.83
  16     South Korea          4.96                               1.20    0.72    4.27    0.00    3.23    0.00    0.63    0.00    0.00    6.69
  17     Belgium              0.71                               0.00    1.57    3.05    9.62    0.00    5.26    1.56    0.82    0.91    0.93
  18     Brazil               0.71                               0.00    1.39    6.10    1.92    3.23    0.00    1.25    0.82    1.82    0.70
  19     Norway               0.00                               0.00    2.17    0.61    0.00    0.00    0.00    0.31    0.55    0.00    0.47
  20     Austria              0.71                               0.00    1.45    0.61    0.00    0.00    0.00    1.25    1.64    0.00    0.93

molecules-24-00640-t010_Table 10

###### 

Comparison of total publications, affiliation number for each radionuclide, and category of radionuclides.

  -------------- ------------ ------------ ------------- ------------- ------------- ------------- --------------------- ------------- ------------- ------------- -------------- -----------
  **CRN**        **^131^I**   **^90^Y**    **^177^Lu**   **^188^Re**   **^186^Re**   **^153^Sm**   **^89^Sr**            **^186^Er**   **Total**                                  
  Papers         4458         1944         1789          596           362           626           528                   36            10339                                      
  Affiliations   5429         2496         2290          718           479           681           681                   46            12820                                      
  **ERN**        **^67^Cu**   **^47^Sc**   **^223^Ra**   **^166^Ho**   **^161^Tb**   **^149^Tb**   **^212^Pb/^212^Bi**   **^225^Ac**   **^213^Bi**   **^211^At**   **^117m^Sn**   **Total**
  Papers         102          65           1115          160           28            21            14                    231           252           75            315            2378
  Affiliations   141          83           1657          164           52            31            19                    320           366           110           429            3372
  -------------- ------------ ------------ ------------- ------------- ------------- ------------- --------------------- ------------- ------------- ------------- -------------- -----------
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###### 

Classification of Journal Subject Areas (JSAs) into macro-areas.

  Macro-areas                      JSA                                                                                                                                                                                       Topic
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Physics                          Energy, engineering, physics and astronomy, materials science                                                                                                                             Research on the production of radionuclides
  Chemistry/Biology/Pharmacology   Agricultural and biological sciences, biochemistry, genetics and molecular biology, chemical engineering, chemistry, environmental science, pharmacology, toxicology, and pharmaceutics   Preclinical research, with particular reference to the development and in vitro/in vivo biological evaluation of radiopharmaceuticals
  Medicine                         Medicine                                                                                                                                                                                  Clinical research
